NICE Ltd
- Country
- 🇮🇱Israel
- Ownership
- -
- Employees
- 8.3K
- Market Cap
- -
- Introduction
NICE Ltd. engages in the provision of enterprise software solutions and services. It operates through the following segments: Customer Engagement, and Financial Crime and Compliance Solutions. The Customer Engagement segment provides suites such as compliance and risk, workforce optimization, operational efficiency, customer experience, and sales and retention. The Financial Crime and Compliance Solutions segment includes for enterprise risk management, anti-money laundering, fraud prevention, and brokerage compliance services. The company was founded on September 28, 1986 and is headquartered in Raanana, Israel.
AKANTIOR® Receives UK Marketing Authorization as First Approved Treatment for Acanthamoeba Keratitis
SIFI's AKANTIOR® (polihexanide 0.08%) has received both Marketing Authorization and Promising Innovative Medicine designation from the UK's MHRA, marking it as the first approved treatment for Acanthamoeba keratitis.
First Biologic Drug for Pulmonary Sarcoidosis in 50 Years Administered at Oxford Hospital
Infliximab, a TNF-α inhibitor, has become the first new drug approved for pulmonary sarcoidosis in over 50 years, following NHS England commissioning with NICE support.
NICE Extends Access to Brineura for CLN2 Batten Disease While Seeking Long-term Solution
NICE has secured continued access to cerliponase alfa (Brineura) for current patients and those starting treatment before December 2025, despite not recommending it for routine NHS use due to cost concerns.
Weight-Loss Injections Show Promise for Obese Children, Reducing Mealtime Conflicts
GLP-1 receptor agonists helped obese children lose 5-16% of body weight after one year of treatment when combined with lifestyle interventions, according to research presented at the European Congress on Obesity.
Shifting Landscape: 5EU Markets Show Significant Changes in HTA Decisions and Drug Pricing in Q1 2025
Italy leads 5EU markets with the highest number of HTA decisions in Q1 2025, accounting for 27% of all assessments, with 82% positive outcomes compared to 95% in 2024.
NHS Explores Pharmacy-Based Weight Loss Injection Program to Expand Access at Prescription Prices
The NHS is reportedly developing a pilot scheme to offer weight loss injections like Ozempic, Wegovy, and Mounjaro through pharmacies at the standard NHS prescription price of £9.90, significantly reducing costs from current private rates of £150 per month.
Cinclus Pharma Advances Linaprazan Glurate Toward Phase III Trials for Acid-Related Diseases
Cinclus Pharma has completed all third-party supplier contracts for its upcoming Phase III study of linaprazan glurate, positioning the next-generation PCAB for advanced clinical evaluation.
Uncomplicated UTIs Impose Significant Economic Burden on Healthcare Systems
Uncomplicated urinary tract infections (uUTIs) lead to substantially higher healthcare costs, with patients incurring over £1200 in annual healthcare expenses compared to £460 for matched controls.
Breakthrough Breast Cancer Drug Capivasertib Approved for NHS Use
A groundbreaking twice-daily pill called capivasertib (Truqap) has been approved for NHS use, targeting hormone receptor-positive HER2-negative breast cancer by blocking cancer growth mechanisms.
UK Government Unveils Life Sciences Strategy to Strengthen Post-Brexit Industry
The UK government has revealed a comprehensive life sciences strategy led by Professor Sir John Bell, aiming to strengthen the sector after Brexit through increased funding and policy reforms.